ResearcherMie UniversityNo recent work listed
Taizo Shiraishi
Matched on OpenAlex author ID A5108354242. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper
Papers 6
- Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle Arrest. Co-author DOI 10.1159/000496831↗
- Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Cli… Co-author DOI 10.1097/mpa.0000000000000597↗
- ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR expression of pancreatic cancer BxPC-3 cells at the invasive front in vitro, and promotes tu… Last author DOI 10.3892/ol.2016.4289↗
- Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of th… Co-author DOI 10.1097/mpa.0000000000000059↗
- Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoper… Co-author DOI 10.1007/s00534-011-0440-3↗
- Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4. Co-author DOI 10.1097/mpa.0b013e3182236442↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kazuki Kanayama · 3 shared papers, 2016–2019 · strength 0.23
- Paper Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle A… DOI 10.1159/000496831↗
- Paper ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR expression of pancreatic cancer BxPC-3 cells at the … DOI 10.3892/ol.2016.4289↗
- Paper Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Bio… DOI 10.1097/mpa.0000000000000597↗
- Yasuhiro Murata · 4 shared papers, 2012–2016 · strength 0.14
- Paper Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Bio… DOI 10.1097/mpa.0000000000000597↗
- Paper Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic d… DOI 10.1097/mpa.0000000000000059↗
- Paper Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic a… DOI 10.1097/mpa.0b013e3182236442↗
- Shuji Isaji · 4 shared papers, 2012–2016 · strength 0.14
- Paper Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Bio… DOI 10.1097/mpa.0000000000000597↗
- Paper Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic d… DOI 10.1097/mpa.0000000000000059↗
- Paper Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic a… DOI 10.1097/mpa.0b013e3182236442↗
- Shugo Mizuno · 4 shared papers, 2012–2016 · strength 0.14
- Paper Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Bio… DOI 10.1097/mpa.0000000000000597↗
- Paper Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic d… DOI 10.1097/mpa.0000000000000059↗
- Paper Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic a… DOI 10.1097/mpa.0b013e3182236442↗
- Hiroyuki Inoue · 4 shared papers, 2012–2016 · strength 0.14
- Paper Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Bio… DOI 10.1097/mpa.0000000000000597↗
- Paper Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic d… DOI 10.1097/mpa.0000000000000059↗
- Paper Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic a… DOI 10.1097/mpa.0b013e3182236442↗
- Masashi Kishiwada · 4 shared papers, 2012–2016 · strength 0.14
- Paper Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Bio… DOI 10.1097/mpa.0000000000000597↗
- Paper Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic d… DOI 10.1097/mpa.0000000000000059↗
- Paper Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic a… DOI 10.1097/mpa.0b013e3182236442↗
- Masatoshi Watanabe · 1 shared paper, 2019 · strength 0.10
- Eri Usugi · 1 shared paper, 2019 · strength 0.10
- Hiroyuki Sakurai · 3 shared papers, 2012–2014 · strength 0.09
- Paper Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic d… DOI 10.1097/mpa.0000000000000059↗
- Paper Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic a… DOI 10.1097/mpa.0b013e3182236442↗
- Paper Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancrea… DOI 10.1007/s00534-011-0440-3↗
- Masaya Fujiwara · 1 shared paper, 2016 · strength 0.08
- Misao Yoneda · 1 shared paper, 2016 · strength 0.04
- Junya Tsuboi · 1 shared paper, 2016 · strength 0.04
- Naohisa Kuriyama · 1 shared paper, 2016 · strength 0.04
- Reiko Yamada · 1 shared paper, 2016 · strength 0.04
- Yoshiyuki Takei · 1 shared paper, 2016 · strength 0.04
- Motoyuki Kobayashi · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.